Disclaimer: PBS listings change frequently. Eligibility criteria, co-payment amounts, and prescriber restrictions are subject to ongoing PBAC review. Always verify the current status of any medication with your GP or the PBS website before making health or financial decisions.
Australia's Pharmaceutical Benefits Scheme has historically provided almost nothing for obesity — effective medications existed, but none were PBS-listed, leaving Australians to pay $350 to $500 per month out of pocket or go without treatment. That changed in 2025 when Wegovy (semaglutide 2.4 mg weekly injectable) became the first obesity-specific medication to receive a PBS listing, cutting costs to under $32 for general patients and under $8 for concession card holders.
The PBS listing also carries symbolic weight: it represents formal government recognition that obesity is a chronic medical condition deserving subsidised treatment on the same footing as type 2 diabetes or cardiovascular disease. This article covers what is currently listed, who qualifies, and what the pipeline looks like through 2027.
Understanding the sparse history of PBS obesity listings requires a grasp of Australia's two-stage pharmaceutical approval process.
TGA approval establishes that a medication is sufficiently safe and effective to be sold in Australia. This is necessary but not sufficient for PBS subsidy. A drug can hold TGA approval and remain unavailable on the PBS indefinitely — Saxenda being the obvious example after a decade on the Australian market without a subsidised listing.
PBAC evaluation is the separate economic and clinical hurdle. The Pharmaceutical Benefits Advisory Committee reviews manufacturer-submitted dossiers comparing a new medication's cost-effectiveness against the existing standard of care. If PBAC recommends listing, the federal government negotiates a price with the manufacturer and formally adds the medication to the PBS schedule.
For obesity medications specifically, PBS listings come with Authority Required prescriptions. Prescribers cannot issue a standard script — they must apply to Services Australia confirming the patient meets specified eligibility criteria. This gatekeeping ensures subsidised access is confined to the clinical population PBAC determined to be cost-effective.
The gap between TGA approval and PBS listing can span years. Companies choose when to submit PBAC dossiers, and PBAC may request additional data or reject submissions outright.
Wegovy is the only medication currently PBS-listed with obesity as its primary indication. Key details for 2026:
Eligibility criteria: Adults with BMI of 35 or above, OR BMI of 30 or above with at least one weight-related comorbidity. Qualifying comorbidities include type 2 diabetes mellitus, obstructive sleep apnoea, cardiovascular disease, hypertension, or dyslipidaemia. Prior lifestyle intervention is also expected to be documented.
PBS co-payments (2026 rates):
These represent a reduction from the $400 to $500 private cost that applied before PBS listing.
Prescriber access: Initial listing restricted Authority to specialists and endocrinologists. Through 2025 and into 2026, prescribing authority has been progressively extending to general practitioners, though some geographic areas still face wait times for specialist-initiated prescriptions.
Continuation criteria: PBS subsidy requires documented weight loss of at least 5% body weight at the six-month review mark. Failure to meet this threshold may result in loss of subsidised continuation.
Ozempic uses the same active ingredient as Wegovy (semaglutide) but at lower doses and with a PBS listing restricted to type 2 diabetes management. It is not PBS-listed for obesity.
The patient overlap is significant — many individuals with obesity also carry a T2DM diagnosis, meaning Ozempic prescribed for glycaemic control delivers meaningful weight loss as a secondary benefit. Prescribers and patients should be clear, however, that using Ozempic for weight loss outside a diabetes indication does not satisfy PBS criteria and would require either a private script or an Authority application under Wegovy's separate obesity listing.
Saxenda (liraglutide 3 mg) remains off the PBS despite holding TGA approval for chronic weight management since 2015. Private cost sits at approximately $350 to $500 per month.
With Wegovy PBS-listed and demonstrating superior weight loss outcomes in head-to-head comparisons, Saxenda's commercial position has weakened considerably. Novo Nordisk has not pursued a PBAC submission for Saxenda's obesity indication in Australia, and with tirzepatide approaching the market, a PBS listing for liraglutide in this indication is unlikely to materialise.
Tirzepatide is a dual GIP and GLP-1 receptor agonist with weight loss efficacy that exceeds semaglutide in head-to-head comparisons. Eli Lilly markets it under two names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Mounjaro is TGA-approved in Australia for T2DM. Zepbound's TGA pathway for the obesity indication is progressing. As of early 2026, neither carries a positive PBAC recommendation for the obesity indication. A PBAC submission is anticipated, with a decision expected through 2026.
The SURMOUNT trial programme produced some of the most striking weight loss data recorded in obesity pharmacotherapy. At the 15 mg weekly maintenance dose, participants lost approximately 22% of body weight on average over 72 weeks — substantially above the approximately 15% observed with semaglutide 2.4 mg in the STEP trials.
A PBAC submission for Zepbound in the obesity indication is anticipated in 2026. Given the efficacy data, the cardiovascular outcomes evidence accumulating in this drug class, and the precedent Wegovy's listing has set, a positive PBAC recommendation is a realistic expectation — with PBS listing likely in 2026 or 2027 depending on price negotiation pace. Eligibility criteria would almost certainly mirror Wegovy's BMI and comorbidity thresholds.
Rybelsus is the oral tablet formulation of semaglutide, PBS-listed for type 2 diabetes at 7 mg and 14 mg doses. The lower doses and oral delivery route produce more modest weight loss than Wegovy's injectable 2.4 mg regimen. Novo Nordisk has not pursued a PBS obesity indication for this formulation, and no obesity-dose oral semaglutide pathway is expected within the 2027 window.
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously — a mechanism that appears to deliver additive metabolic benefits beyond dual or single agonism. Phase 2 data showed average body weight reductions of approximately 24% at 48 weeks, the highest pharmacological weight loss figures recorded to date. Phase 3 trials are underway.
A TGA submission and any subsequent PBAC evaluation would realistically fall into a 2027 or later window. Retatrutide represents a meaningful horizon for Australian patients, but it is not an imminent access story.
PBS criteria — BMI of 35 or above, or BMI of 30 or above with a documented comorbidity — leave a meaningful population without subsidised access. A person with BMI of 32 and no formally diagnosed comorbidity does not qualify despite sitting within the clinical obesity range. The SELECT cardiovascular outcomes trial, which enrolled participants from BMI 27, strengthens the case for eventually broadening thresholds, but PBAC cost-effectiveness modelling at initial listing tends to be conservative.
The practical implication: if you have conditions that could qualify as comorbidities — hypertension, dyslipidaemia, sleep apnoea — but they haven't been formally diagnosed and coded, that conversation with your GP is worth having before concluding you don't meet criteria.
GLP-1 medications experienced widespread global supply shortages from 2023 through mid-2025 as demand outpaced manufacturing capacity. In Australia, the TGA activated provisions allowing compounding pharmacies to produce semaglutide and tirzepatide under declared shortage conditions — a regulatory grey zone that served as a stopgap.
As brand supply stabilised through late 2025, TGA moved to tighten compounding rules. Patients currently accessing compounded GLP-1s should expect that pathway to close or become materially restricted through 2026, making PBS access to brand medications the primary affordable route for qualifying patients.
| Access Route | Approximate Monthly Cost | Key Considerations |
|---|---|---|
| PBS Wegovy — concession | ~$7.70 | Requires meeting BMI/comorbidity criteria |
| PBS Wegovy — general patient | ~$31.60 | Authority Required prescription |
| Private Saxenda | ~$350–500 | TGA approved, no PBS subsidy |
| Private Wegovy (if PBS criteria not met) | ~$400–500 | Full private cost |
| Compounded semaglutide (domestic) | ~$80–180 | Regulatory status tightening through 2026 |
| Offshore/medical tourism sourcing | ~$50–150 | Significant risks — see below |
The offshore route carries risks the cost comparison doesn't capture: cold chain integrity cannot be verified, dosing accuracy is unconfirmed, and there is no prescribing oversight or regulatory recourse. For patients who don't meet PBS criteria, supervised access through a prescriber remains the safer path even at private cost.
One of the most clinically important findings from long-term GLP-1 trials is what happens when treatment stops. The STEP 4 withdrawal trial found that participants who discontinued semaglutide regained approximately two-thirds of their lost weight within one year of stopping. Cardiometabolic markers — blood pressure, blood glucose, lipid levels — also drifted back toward pre-treatment baselines.
This has practical implications for PBS policy. Obesity medicine specialists increasingly frame GLP-1 medications the same way as antihypertensives or statins: not a fixed course with a defined endpoint, but ongoing treatment for a chronic condition. PBS continuation criteria involving periodic six- and twelve-month reviews can create friction for patients who need indefinite therapy.
Weight regain after stopping is not a personal failure — it reflects the chronic neurobiology of obesity, where the body defends its pre-treatment weight through hormonal adaptation. Having a clear long-term plan, including financial contingency if PBS criteria change, is worth discussing at the point of initiation.
Step 1 — Consult your GP. Bring your current height and weight, recent blood pressure readings, and any pathology results on file. Be ready to discuss your weight history and any comorbidities.
Step 2 — Document eligibility. Your GP will calculate your BMI and assess whether comorbidities (T2DM, hypertension, sleep apnoea, dyslipidaemia, CVD) are formally diagnosed and coded. If they are present but undocumented, formalising that diagnosis may change your eligibility.
Step 3 — Authority prescription. If you meet criteria, your GP applies for Authority through Services Australia. In some areas, initial prescribing may still require specialist initiation — your GP can advise and refer if needed. Telehealth obesity medicine services have expanded access in regional areas.
Step 4 — Titration. Wegovy starts at 0.25 mg weekly and increases gradually over approximately 16 to 20 weeks to the 2.4 mg maintenance dose. Gastrointestinal side effects are most common during escalation and typically improve as the body adjusts.
Step 5 — Six-month review. Continued PBS subsidy requires a minimum 5% body weight reduction at six months. This review is also an opportunity to assess tolerability, adjust the titration timeline if needed, and plan for ongoing management.
Throughout this process, lifestyle modification — dietary quality, sleep, movement — accompanies pharmacotherapy rather than being replaced by it. For those interested in the mechanism science and emerging compound research underpinning this class, GLP-1 peptide research continues to advance rapidly.
Australia's PBS landscape for obesity treatment shifted materially with Wegovy's 2025 listing — reducing monthly costs from several hundred dollars to under $32 for qualifying patients. Current eligibility requires BMI of 35 or above, or BMI of 30 or above with a documented weight-related comorbidity, accessed through an Authority Required prescription process.
Tirzepatide (Zepbound) is the next meaningful milestone. With SURMOUNT trial data showing approximately 22% average weight loss and a PBAC submission anticipated in 2026, an Australian PBS listing in the 2026 to 2027 window is a realistic expectation. Retatrutide, with phase 3 trials showing approximately 24% average weight loss, extends the pipeline into 2027 and beyond.
For Australians who currently meet criteria, PBS-subsidised access to Wegovy is a genuine clinical opportunity at a cost that is genuinely accessible. For those who don't quite qualify, the eligibility criteria are worth re-examining with a GP — particularly where comorbidities may be present but not yet formally documented.
Co-payment figures cited reflect 2026 PBS general and concession rates and are subject to annual indexation. Verify current costs at pbs.gov.au. Eligibility criteria are based on PBAC recommendations and published guidelines; final criteria for any listed medication are confirmed at gazette listing. This article is for educational purposes only and does not constitute medical advice.
Eli Lilly's orforglipron is the first non-peptide oral GLP-1 agonist with full Phase 3 data. This guide covers the ATTAIN-1 obesity trial, the ACHIEVE-1 T2D trial, weight loss versus injectable semaglutide and tirzepatide, side-effect profile, and Australian timeline implications.
A research-backed explainer on orforglipron (Foundayo) — the first oral small-molecule GLP-1 receptor agonist approved for weight loss, why no-restriction dosing matters, what the ATTAIN trials showed, and how it compares to injectables and oral semaglutide.
A detailed breakdown of the TRIUMPH-1 Phase 3 trial results for retatrutide — the triple-hormone agonist that achieved up to 28.3% mean weight loss at 80 weeks and ~30.3% in a higher-BMI subgroup at 104 weeks.